Do analysts prefer CUPR or GRAY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, CUPR or GRAY?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Graybug Vision. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 106.51 -$3.63M N/A N/A Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A

Is CUPR or GRAY more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Cuprina Holdings (Cayman) N/A N/A N/A Graybug Vision N/A -77.61% -71.34%

Do analysts recommend BGMS or GRAY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BGMS or GRAY more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% Graybug Vision N/A -77.61% -71.34%

Do analysts rate GRAY or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Graybug Vision. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GRAY or DCOY more profitable?

Graybug Vision's return on equity of -77.61% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Graybug Vision N/A -77.61% -71.34% Decoy Therapeutics N/A -395.42% -193.30%

Which has preferable valuation & earnings, LABT or GRAY?

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Graybug Vision. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lakewood-Amedex Biotherapeutics N/A N/A N/A N/A N/A Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A

Is LABT or GRAY more profitable?

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Lakewood-Amedex Biotherapeutics N/A N/A N/A Graybug Vision N/A -77.61% -71.34%

Which has preferable valuation & earnings, GRAY or ORGS?

Graybug Vision has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Graybug Vision $426.96M 0.00 -$35.60M -$24.23 N/A Orgenesis $662K 3.12 -$55.36M -$11.51 N/A

Is GRAY or ORGS more profitable?

Graybug Vision has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Graybug Vision's return on equity. Company Net Margins Return on Equity Return on Assets Graybug Vision N/A -77.61% -71.34% Orgenesis -3,827.81% N/A -130.18%

Graybug Vision (GRAY) Competitors

Compare

GRAY vs. CUPR, BGMS, DCOY, LABT, and ORGS

Should you buy Graybug Vision stock or one of its competitors? MarketBeat compares Graybug Vision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Graybug Vision include Cuprina Holdings (Cayman) (CUPR), Cyclacel Pharmaceuticals (BGMS), Decoy Therapeutics (DCOY), Lakewood-Amedex Biotherapeutics (LABT), and Orgenesis (ORGS).

How does Graybug Vision compare to Cuprina Holdings (Cayman)?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

49.9% of Graybug Vision shares are held by institutional investors. 7.9% of Graybug Vision shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cuprina Holdings (Cayman) has a beta of -1.1, meaning that its stock price is 210% less volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Graybug Vision	N/A	-77.61%	-71.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Graybug Vision. MarketBeat recorded 1 mentions for Cuprina Holdings (Cayman) and 0 mentions for Graybug Vision. Cuprina Holdings (Cayman)'s average media sentiment score of 1.11 beat Graybug Vision's score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Graybug Vision	Neutral

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Graybug Vision.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	106.51	-$3.63M	N/A	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

Summary

Cuprina Holdings (Cayman) beats Graybug Vision on 6 of the 10 factors compared between the two stocks.

How does Graybug Vision compare to Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Cyclacel Pharmaceuticals has higher earnings, but lower revenue than Graybug Vision. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	7.80	-$3M	-$4.54	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cyclacel Pharmaceuticals has a beta of -0.38, suggesting that its stock price is 138% less volatile than the broader market. Comparatively, Graybug Vision has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

In the previous week, Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Neutral
Graybug Vision	Neutral

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Graybug Vision	N/A	-77.61%	-71.34%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cyclacel Pharmaceuticals beats Graybug Vision on 7 of the 10 factors compared between the two stocks.

How does Graybug Vision compare to Decoy Therapeutics?

Graybug Vision (NASDAQ:GRAY) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Decoy Therapeutics is more favorable than Graybug Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Graybug Vision	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Decoy Therapeutics had 5 more articles in the media than Graybug Vision. MarketBeat recorded 5 mentions for Decoy Therapeutics and 0 mentions for Graybug Vision. Decoy Therapeutics' average media sentiment score of 0.22 beat Graybug Vision's score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Graybug Vision	Neutral
Decoy Therapeutics	Neutral

Graybug Vision's return on equity of -77.61% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Decoy Therapeutics has lower revenue, but higher earnings than Graybug Vision. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Summary

Graybug Vision and Decoy Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Graybug Vision compare to Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Graybug Vision (NASDAQ:GRAY) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Lakewood-Amedex Biotherapeutics' return on equity of 0.00% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A
Graybug Vision	N/A	-77.61%	-71.34%

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Graybug Vision.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A

49.9% of Graybug Vision shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score.

Company	Overall Sentiment
Lakewood-Amedex Biotherapeutics	Neutral
Graybug Vision	Neutral

Summary

Graybug Vision beats Lakewood-Amedex Biotherapeutics on 3 of the 5 factors compared between the two stocks.

How does Graybug Vision compare to Orgenesis?

Graybug Vision (NASDAQ:GRAY) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Graybug Vision's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Graybug Vision	Neutral
Orgenesis	Neutral

Graybug Vision has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.15, suggesting that its share price is 215% more volatile than the broader market.

49.9% of Graybug Vision shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 7.9% of Graybug Vision shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Graybug Vision has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Graybug Vision	$426.96M	0.00	-$35.60M	-$24.23	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Graybug Vision has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Graybug Vision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Graybug Vision	N/A	-77.61%	-71.34%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

Graybug Vision beats Orgenesis on 6 of the 10 factors compared between the two stocks.

Get Graybug Vision News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRAY vs. The Competition

Export

Metric	Graybug Vision	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.67M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-0.61	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.55	99.42
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	-$35.60M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	24.68%	4.41%	5.25%	3.81%
1 Year Performance	-34.16%	49.43%	33.29%	23.90%

Graybug Vision Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRAY Graybug Vision	N/A	N/A	N/A	-34.2%	$1.67M	$426.96M	N/A	27	Gap Up High Trading Volume
CUPR Cuprina Holdings (Cayman)	0.6151 of 5 stars	$5.33 -5.7%	N/A	N/A	$5.20M	$40K	N/A	14	Gap Down
BGMS Cyclacel Pharmaceuticals	0.4658 of 5 stars	$0.60 -0.2%	N/A	N/A	$3.32M	$1.53M	N/A	14	Gap Down
DCOY Decoy Therapeutics	3.0473 of 5 stars	$5.52 -6.8%	$30.00 +443.5%	N/A	$3.15M	N/A	N/A	20	Gap Down
LABT Lakewood-Amedex Biotherapeutics	N/A	$3.51 +2.3%	N/A	N/A	$2.46M	N/A	N/A	5	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRAY) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Graybug Vision (GRAY) Competitors

GRAY vs. CUPR, BGMS, DCOY, LABT, and ORGS

How does Graybug Vision compare to Cuprina Holdings (Cayman)?

Summary

How does Graybug Vision compare to Cyclacel Pharmaceuticals?

Summary

How does Graybug Vision compare to Decoy Therapeutics?

Summary

How does Graybug Vision compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Graybug Vision compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Graybug Vision (GRAY) Competitors

GRAY vs. CUPR, BGMS, DCOY, LABT, and ORGS

How does Graybug Vision compare to Cuprina Holdings (Cayman)?

Do institutionals and insiders hold more shares of CUPR or GRAY?

Which has more volatility & risk, CUPR or GRAY?

Is CUPR or GRAY more profitable?

Do analysts prefer CUPR or GRAY?

Does the media prefer CUPR or GRAY?

Which has better earnings & valuation, CUPR or GRAY?

Summary

How does Graybug Vision compare to Cyclacel Pharmaceuticals?

Which has preferable earnings and valuation, BGMS or GRAY?

Do institutionals & insiders have more ownership in BGMS or GRAY?

Which has more volatility & risk, BGMS or GRAY?

Does the media favor BGMS or GRAY?

Is BGMS or GRAY more profitable?

Do analysts recommend BGMS or GRAY?

Summary

How does Graybug Vision compare to Decoy Therapeutics?

Do analysts rate GRAY or DCOY?

Do insiders & institutionals believe in GRAY or DCOY?

Does the media prefer GRAY or DCOY?

Is GRAY or DCOY more profitable?

Which has stronger valuation and earnings, GRAY or DCOY?

Which has more risk & volatility, GRAY or DCOY?

Summary

How does Graybug Vision compare to Lakewood-Amedex Biotherapeutics?

Is LABT or GRAY more profitable?

Which has preferable valuation & earnings, LABT or GRAY?

Do institutionals & insiders believe in LABT or GRAY?

Does the media prefer LABT or GRAY?

Summary

How does Graybug Vision compare to Orgenesis?

Does the media prefer GRAY or ORGS?

Which has more volatility and risk, GRAY or ORGS?

Do insiders and institutionals hold more shares of GRAY or ORGS?

Which has preferable valuation & earnings, GRAY or ORGS?

Is GRAY or ORGS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRAY vs. The Competition

Graybug Vision Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools